ORIC Pharmaceuticals Announces Focused Clinical Plans and Extended Cash Runway

ORIC Pharmaceuticals is refining its clinical strategy for its lead oncology programs, ORIC-944 and ORIC-114, while extending its cash runway into 2027. The company plans to initiate its first Phase 3 trial for ORIC-944, a PRC2 inhibitor for metastatic castration-resistant prostate cancer (mCRPC), in the first half of 2026. Additionally, ORIC-114, an EGFR/HER2 inhibitor targeting non-small cell lung cancer (NSCLC), is set for registrational trials in 2026, focusing on first-line treatment settings where the need is greatest. These strategic shifts align with promising internal and external clinical data supporting the therapies' potential.

With accelerated development milestones, ORIC aims to report dose escalation data for ORIC-944 in early 2025, followed by an update later in the year. Meanwhile, ORIC-114 is advancing across multiple patient cohorts, with key data expected in the second half of 2025 and early 2026. CEO Jacob M. Chacko emphasized that these focused registrational plans will optimize resource allocation and maximize commercial impact. By concentrating efforts on high-value first-line indications, ORIC is positioning itself for significant clinical and financial progress in the coming years.